Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.
Drug Development
Korro secures approvals in Australia to commence AATD trial of KRRO-110
Arch Biopartners doses first subject in trial of acute kidney injury treatment
Disc Medicine secures $200m financing to support trials
OncoResponse reports data from Phase I solid tumour treatment trial
Adapting diabetes clinical trials to embrace underrepresented communities
Genelux doses first subject in Phase II trial of NSCLC treatment
Gilead and MSD to advance once-weekly HIV treatment to Phase III
